Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-08-2014 | Laryngology

Cilengitide, a small molecule antagonist, targeted to integrin αν inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro

Authors: Jing Ting Wang, Ying Liu, Xuan Kan, Ming Liu, Jian Guang Lu

Published in: European Archives of Oto-Rhino-Laryngology | Issue 8/2014

Abstract

Cilengitide is a chemical synthesis cyclopeptide containing RGD sequence, which can be used as a small molecule antagonist targeted to integrin αν (ITGAV). The aim of present study was to investigate the effect on proliferation and cell apoptosis of the cilengitide in laryngeal cancer cells. In the study, we have treatmented the cultured cells of laryngeal cancer (Hep-2) with cilengitide. After the medication, the proliferation of the Hep-2 cells was detected by MTT assay, the expression of ITGAV was detected by RT-PCR and the activity of caspase-3 protein was detected by a specialized kit. RGD linear peptides (GRGDSP), non-RGD linear peptide (GRGESP), and 5-fluorouracil (5-Fu) were used as controls. Results showed that the proliferation of Hep-2 cells was signally inhibited by the cilengitide with a time and dose compliance. Its inhibition effect was significantly higher than that of 5-Fu and GRGDSP, but the GRGESP showed no obvious inhibitory effect. After intervene of cilengitide, the activity of caspase-3 protein of Hep-2 cells was significantly increased, and the expression of ITGAV was significantly decreased. 5-Fu significantly inhibited the proliferation of Hep-2 cells, but no significant changes of ITGAV expression were observed. In conclusion, cilengitide can significantly down-regulate ITGAV expression and inhibit cell proliferation in laryngeal cancer cells, it will also to induce cell apoptosis through caspase-3 pathway. Therefore, it could be as a kind of effective chemotherapy drugs that will be used in clinical treatment of the laryngeal cancer.

Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51(18 Suppl):5054s–5059sPubMed

Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11(1):31–44PubMedCrossRef

Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8(5):724–730PubMedCrossRef

Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285(5430):1028–1032PubMedCrossRef

Haubner R, Finsinger D, Kessler H (1997) Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 28(39):1374–1389CrossRef

Heckmann D, Kessler H (2007) Design and chemical synthesis of integrin ligands. Method Enzymol 426:463–503CrossRef

Liekens S, De Clercq E, Neyts J (2001) Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61(3):253–270PubMedCrossRef

Tucker G (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8(2):96–103PubMedCrossRef

Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10(10):753–768PubMedCentralPubMedCrossRef

10.

Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651–1657PubMedCrossRef

11.

MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26(6):919–924PubMedCrossRef

12.

Lu JG, Sun YN, Wang C, Jin DJ, Liu M (2009) Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation. Eur Arch Otorhinolaryngol 266(1):89–96PubMedCrossRef

13.

Lu JG, Li Y, Li L, Kan X (2011) Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol 137(11):1613–1618PubMedCrossRef

14.

Li F, Liu Y, Kan X, Li Y, Liu M, Lu JG (2013) Elevated expression of integrin αv and β5 subunit in laryngeal squamous-cell carcinoma associated with lymphatic metastasis and angiogenesis. Pathol Res Pract 209(2):105–109PubMedCrossRef

15.

Humphries M, Akiyama S, Komoriya A, Olden K, Yamada K (1986) Identification of an alternatively spliced site in human plasma fibronectin that mediates cell type-specific adhesion. J Cell Biol 103(6 Pt 2):2637–2647PubMedCrossRef

16.

Jovanovic J, Takagi J, Choulier L, Abrescia NG, Stuart DI, van der Merwe PA, Mardon HJ, Handford PA (2007) AlphaV beta6 is a novel receptor for human fibrillin-1. Comparative studies of molecular determinants underlying integrin-rgd affinity and specificity. J Biol Chem 282(9):6743–6751PubMedCrossRef

17.

Hirasawa M, Shijubo N, Uede T, Abe S (1994) Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines. Br J Cancer 70(3):466–473PubMedCentralPubMedCrossRef

18.

Kumagai H, Tajima M, Ueno Y, Giga-Hama Y, Ohba M (1991) Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem Biophys Res Commun 177(1):74–82PubMedCrossRef

19.

Ten Hagen TL, Seynhaeve AL, de Wiel-Ambagtsheer GA, de Bruijn EA, van Tiel ST, Ruegg C, Meyring M, Grell M, Goodman SL, Eggermont AM (2013) The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. Int J Cancer 132(11):2694–2704PubMedCrossRef

20.

Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S, Lieberman F, Wen P, Poetzsch S, Picard M, Prados M, Kuhn J (2007) Tumor tissue delivery of cilengitide after intravenous administration to patients with recurrent glioblastoma. Preliminary data from NABTC protocol 03-02. Neuro Oncol 9:525

21.

Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 65(5):1536–1543PubMedCrossRef

22.

Anuradha CD, Kanno S, Hirano S (2000) RGD peptide-induced apoptosis in human leukemia HL-60 cells requires caspase-3 activation. Cell Biol Toxicol 16(5):275–283PubMedCrossRef

23.

Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Akbar AN, Lord JM, Salmon M (1999) RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397(6719):534–539PubMedCrossRef

Title: Cilengitide, a small molecule antagonist, targeted to integrin αν inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro
Authors: Jing Ting Wang
Ying Liu
Xuan Kan
Ming Liu
Jian Guang Lu
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Oto-Rhino-Laryngology / Issue 8/2014
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-014-2918-5

At a glance: The STEP trials

Springer Medicine

Cilengitide, a small molecule antagonist, targeted to integrin αν inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Depression, Anxiety and Stress Scale in patients with tinnitus and hearing loss

Respiratory complications after diode-laser-assisted tonsillotomy

Objective versus subjective measurements of palatine tonsil size in adult patients with obstructive sleep apnea/hypopnea syndrome

Cricotracheal resection for laryngeal invasion by thyroid carcinoma: our experience

Diagnostic value of cone-beam CT in histologically confirmed otosclerosis

Time interval between primary radiotherapy and salvage laryngectomy: a predictor of pharyngocutaneous fistula formation